{"id":78246,"date":"2023-09-25T09:39:35","date_gmt":"2023-09-25T04:09:35","guid":{"rendered":"http:\/\/finservwealth.com\/strides-pharma-trades-2-up-after-usfda-nod-for-drug-to-reduce-heart-issues\/"},"modified":"2023-09-25T09:39:35","modified_gmt":"2023-09-25T04:09:35","slug":"strides-pharma-trades-2-up-after-usfda-nod-for-drug-to-reduce-heart-issues","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/strides-pharma-trades-2-up-after-usfda-nod-for-drug-to-reduce-heart-issues\/","title":{"rendered":"Strides Pharma trades 2% up after USFDA nod for drug to reduce heart issues"},"content":{"rendered":"<p> The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved.<\/p><div id=\"finse-3845144773\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/strides-pharma-trades-2after-usfda-nod-for-drug-to-reduce-heart-issues_17248681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved. The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/strides-pharma-trades-2after-usfda-nod-for-drug-to-reduce-heart-issues_17248681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/strides-pharma-trades-2after-usfda-nod-for-drug-to-reduce-heart-issues_17248681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved. The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/strides-pharma-trades-2after-usfda-nod-for-drug-to-reduce-heart-issues_17248681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230  ANDAs have been approved.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-78246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/S\/STRIDES-PHARMA-SCIENCE_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/78246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=78246"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/78246\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=78246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=78246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=78246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}